Advertisement

Intravenous Recombinant Tissue Plasminogen Activator and Ischemic Stroke: Focused Update of 2010 Clinical Practice Advisory From the American Academy of Emergency Medicine

      Abstract

      Background

      Stroke treatment is a continuum that begins with the rapid identification of symptoms and treatment with transition to successful rehabilitation. Therapies for acute ischemic stroke (AIS) may vary based on anatomic location, interval from symptom onset, and coexisting health conditions. Successful therapy requires a seamless systematic approach with coordination from prehospital environment through acute management at medical facilities to disposition and long-term care of the patient. The emergency physician must balance the benefits and risks of alteplase recombinant tissue plasminogen activator (rtPA) for AIS management.

      Objective

      We review the recent medical literature on the topic of AIS and assess intravenous rtPA for the following questions: 1) is there any applicable, new, high-quality evidence that the benefits of intravenous rtPA are justified in light of the harms associated with it, and 2) if so, does the evidence clarify which patients, if any, are most likely to benefit from the treatment.

      Methods

      A MEDLINE literature search from January 2010 to October 2016 and limited to human studies written in English for articles with keywords of cerebrovascular accident and (thromboly* OR alteplase). Guideline statements and nonsystematic reviews were excluded. Studies targeting differences between specific populations (males vs. females) were excluded. Studies identified then underwent a structured review from which results could be evaluated.

      Results

      Three hundred twenty-two papers on thrombolytic use were screened and nine appropriate articles were rigorously reviewed and recommendations given.

      Conclusions

      No new studies published between 2010 and 2016 meaningfully reduced uncertainty regarding our understanding of the benefits and harms of intravenous rtPA for AIS. Discussions regarding benefit and harm should occur for patients, and risk prediction scores may facilitate the conversation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benjamin E.J.
        • Blaha M.J.
        • Chiuve S.E.
        • et al.
        Heart disease and stroke statistics—2017 update: a report from the American Heart Association.
        Circulation. 2017; 135: e146-e603
        • Kochanek K.D.
        • Xu J.Q.
        • Murphy S.L.
        • et al.
        Mortality in the United States, 2013.
        (NCHS Data Brief, No. 178) National Center for Health Statistics, Centers for Disease Control and Prevention, Department of Health and Human Services, Hyattsville, MD2014
        • Centers for Disease Control and Prevention, National Center for Health Statistics
        Underlying cause of death 1999-2013 on CDC WONDER online database, released 2015. Data are from the multiple cause of death files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program.
        (Available at:)
        http://wonder.cdc.gov/ucd-icd10.html
        Date accessed: October 23, 2017
        • National Center for Health Statistics National Health Interview Survey, 2014
        Public-use data file and documentation: NCHS tabulations.
        (Available at:)
        • Ovbiagele B.
        • Goldstein L.B.
        • Higashida R.T.
        • et al.
        Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association.
        Stroke. 2013; 44: 2361-2375
        • Mozaffarian D.
        • Benjamin E.J.
        • Go A.S.
        • et al.
        Heart disease and stroke statistics–2015 Update: a report from the American Heart Association.
        Circulation. 2015; 131: e29-e32
        • Jauch E.C.
        • Saver J.L.
        • Adams H.P.
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 870-947
        • Meurer W.J.
        • Majersik J.J.
        • Frederiksen S.M.
        • et al.
        Provider perceptions of barriers to the emergency use of tPA for acute ischemic stroke: a qualitative study.
        BMC Emerg Med. 2011; 11: 5
        • Smith E.E.
        • Fonarow G.C.
        • Reeves M.J.
        • et al.
        outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke.
        Stroke. 2011; 42: 3110-3115
        • Khatri P.
        • Conaway M.R.
        • Johnston K.C.
        Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke.
        Stroke. 2012; 43: 560-562
        • Tsivgoulis G.
        • Zand R.
        • Katsanos A.H.
        • et al.
        Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis.
        Stroke. 2015; 46: 1281-1287
        • Shi L.
        • Zhang M.
        • Liu H.
        • et al.
        Safety and outcome of thrombolysis in mild stroke: a meta-analysis.
        Med Sci Monit. 2014; 20: 2117-2124
        • Emberson J.
        • Lees K.R.
        • Lyden P.
        • et al.
        Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
        Lancet. 2014; 384: 1929-1935
        • Wardlaw J.M.
        • Murray V.
        • Berge E.
        • et al.
        Thrombolysis for acute ischaemic stroke.
        Cochrane Database Syst Rev. 2014; 7: CD000213
        • Whiteley W.N.
        • Slot K.B.
        • Fernandes P.
        • et al.
        Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies.
        Stroke. 2012; 43: 2904-2909
        • Bhatnagar P.
        • Sinha D.
        • Parker R.A.
        • et al.
        Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age.
        J Neurol Neurosurg Psychiatry. 2011; 82: 712-717
        • IST-3 Collaborative Group
        Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial.
        Stroke. 2014; 45: 1000-1006
        • IST-3 Collaborative Group
        Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (Third International Stroke Trial).
        Stroke. 2014; 45: 3612-3617
        • IST-3 Collaborative Group
        The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (The Third International Stroke Trial [IST-3]): a randomised controlled trial.
        Lancet. 2012; 379: 2352-2363
        • Stroke Unit Trialists' Collaboration
        Organised inpatient (stroke unit) care for stroke.
        Cochrane Database Syst Rev. 2007; 4: CD000197
        • Mattishent K.
        • Kwok C.S.
        • Mahtani A.
        • et al.
        Prognostic indices for early mortality in ischaemic stroke- meta-analysis.
        Acta Neurol Scand. 2016; 133: 41-48
        • Lyden P.D.
        In anticipation of International Stroke Trial-3 (IST-3).
        Stroke. 2012; 43: 1691-1694
        • Mazya M.
        • Egido J.A.
        • Ford G.A.
        • et al.
        Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
        Stroke. 2012; 43: 1524-1531
        • Saver J.L.
        Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke.
        Arch Neurol. 2004; 61: 1066-1070
        • Saver J.L.
        • Gombien J.
        • Grotta J.
        • et al.
        Number needed to treat to benefit and to harm for IV tPA therapy in the 3-4.5 hour window: joint outcome table analysis of The ECASS 3 Trial.
        Stroke. 2009; 30: 2433-2437
        • Fonarow G.C.
        • Reeves M.J.
        • Zhao X.
        • et al.
        Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke.
        Circulation. 2010; 121: 879-891
        • Barnes L.L.
        • Mendes de Leon C.F.
        • Lewis T.T.
        • et al.
        Perceived discrimination and mortality in a population-based study of older adults.
        Am J Public Health. 2008; 98: 1241-1247
        • Luker J.A.
        • Wall K.
        • Bernhardt J.
        • et al.
        Patients' age as a determinant of care received following acute stroke: a systematic review.
        BMC Health Serv Res. 2011; 11: 161
        • Saposnik G.
        • Kapral M.K.
        • Coutts S.B.
        • et al.
        Do all groups benefit from organized inpatient stroke care?.
        Stroke. 2009; 40: 3321-3327
        • Xian Y.
        • Holloway R.G.
        • Chan P.S.
        • et al.
        Association between stroke center hospitalization for acute ischemic stroke and mortality.
        JAMA. 2011; 305: 373-380
        • Bravata D.M.
        • Wells C.K.
        • Lo A.C.
        • et al.
        Processes of care associated with acute stroke outcomes.
        Arch Intern Med. 2010; 170: 804-810
        • Kepplinger J.
        • Barlinn K.
        • Deckert S.
        • et al.
        Safety and efficacy of thrombolysis in telestroke: a systematic review and meta-analysis.
        Neurology. 2016; 87: 1344-1351
        • Anderson C.S.
        • Woodward M.
        • Arima H.
        • et al.
        Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED).
        Int J Stroke. 2015; 10: 1313-1315
      1. Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke (TAIS).
        (Available at:)
      2. Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND) trial.
        (Available at:)
      3. Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients With Suspected Large Vessel Occlusion (RACECAT) trial.
        (Available at:)